

Statute. The complainant requests that the Commission institute an investigation and, after the investigation, issue a limited exclusion order and cease and desist orders.

ADDRESSES: The complaint, except for any confidential information contained therein, may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. Hearing impaired individuals are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at (202) 205-2000. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>.

FOR FURTHER INFORMATION CONTACT: Jessica Mullan, Office of the Secretary, Docket Services Division, U.S. International Trade Commission, telephone (202) 205-1802.

SUPPLEMENTARY INFORMATION:

Authority: The authority for institution of this investigation is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.10 of the Commission's Rules of Practice and Procedure, 19 CFR 210.10 (2021).

Scope of Investigation: Having considered the complaint, the U.S. International Trade Commission, on January 7, 2022, ordered that—

(1) Pursuant to subsection (b) of section 337 of the Tariff Act of 1930, as amended, an investigation be instituted to determine whether there is a violation of subsection (a)(1)(B) of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain products identified in paragraph (2) by reason of infringement of one or more of claims 1-3, 5, 9-11, 15, and 17-20 of the '511 patent; claims 1-8 and 11-20 of the '705 patent; claims 1-9, 13-19, and 21 of the '749 patent; claims 1, 9, and 14 of the '598 patent; claims 1-4 of the '562 patent; and claims 11, 12, 14, and 15 of the '932 patent; and whether an industry in the United States exists as required by subsection (a)(2) of section 337;

(2) Pursuant to section 210.10(b)(1) of the Commission's Rules of Practice and Procedure, 19 CFR 210.10(b)(1), the plain language description of the accused products or category of accused products, which defines the scope of the

investigation, is "footwear with a knitted upper or with an upper with knitted elements";

(3) For the purpose of the investigation so instituted, the following are hereby named as parties upon which this notice of investigation shall be served:

(a) The complainant is: Nike, Inc., One Bowerman Drive, Beaverton, OR 97005

(b) The respondents are the following entities alleged to be in violation of section 337, and are the parties upon which the complaint is to be served: adidas AG, World of Sports, Adi-Dassler-Strasse 1, 91074 Herzogenaurach, Germany; adidas North America, Inc., adidas Village, 5055 N Greeley Avenue, Portland, OR 97217; adidas America, Inc., adidas Village, 5055 N Greeley Avenue, Portland, OR 97217

(4) For the investigation so instituted, the Chief Administrative Law Judge, U.S. International Trade Commission, shall designate the presiding Administrative Law Judge.

The Office of Unfair Import Investigations is not participating as a party to this investigation.

Responses to the complaint and the notice of investigation must be submitted by the named respondents in accordance with section 210.13 of the Commission's Rules of Practice and Procedure, 19 CFR 210.13. Pursuant to 19 CFR 201.16(e) and 210.13(a), as amended in 85 FR 15798 (March 19, 2020), such responses will be considered by the Commission if received not later than 20 days after the date of service by the complainant of the complaint and the notice of investigation. Extensions of time for submitting responses to the complaint and the notice of investigation will not be granted unless good cause therefor is shown.

Failure of a respondent to file a timely response to each allegation in the complaint and in this notice may be deemed to constitute a waiver of the right to appear and contest the allegations of the complaint and this notice, and to authorize the administrative law judge and the Commission, without further notice to the respondent, to find the facts to be as alleged in the complaint and this notice and to enter an initial determination and a final determination containing such findings, and may result in the issuance of an exclusion order or a cease and desist order or both directed against the respondent.

By order of the Commission.

Issued: January 10, 2022.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2022-00600 Filed 1-12-22; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—ODVA, Inc.

Notice is hereby given that, on January 4, 2022, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), ODVA, Inc. ("ODVA") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Asyrl SA, Villaz-St-Pierre, SWITZERLAND; Guangdong OPT Technology Co., Ltd., Dongguan, PEOPLE'S REPUBLIC OF CHINA; Roboteq, Inc., Scottsdale, AZ; Uson L.P., Houston, TX; and Shanghai JAKA Robotics Ltd., Shanghai, PEOPLE'S REPUBLIC OF CHINA, have been added as parties to this venture.

Also, Acuity Brands, Inc., Conyers, GA; Lanmark Controls Inc., Londonderry, NH; Tokyo Keiso Co., Ltd., Tokyo, JAPAN; Hangzhou Hikrobot Technology Co., Ltd., Hangzhou, PEOPLE'S REPUBLIC OF CHINA; Bayshore Networks, Inc., Durham, NC; and FACTS, Inc., Cuyahoga Falls, OH, have withdrawn as parties to this venture.

In addition, JANOME Corporation has changed its name to Janome Sewing Machine Co., Ltd., Tokyo, JAPAN; KEBA Industrial Automation GmbH to KEBA AG, Linz, AUSTRIA; and NTI AG to LinMot, Spreitenbach, SWITZERLAND.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and ODVA intends to file additional written notifications disclosing all changes in membership.

On June 21, 1995, ODVA filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on February 15, 1996 (61 FR 6039).

The last notification was filed with the Department on October 5, 2021. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on October 22, 2021 (86 FR 58690).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2022-00613 Filed 1-12-22; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—The Integrated Photonics Institute for Manufacturing Innovation Operating Under the Name of the American Institute for Manufacturing Integrated Photonics

Notice is hereby given that, on November 23, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), the Integrated Photonics Institute for Manufacturing Innovation operating under the name of the American Institute for Manufacturing Integrated Photonics (“AIM Photonics”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Regents of the University of Minnesota, Minneapolis, MN; Buhler Inc. Leybold Optics, Cary, NC; and Spark Photonics Design, Inc., Waltham, MA, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and AIM Photonics intends to file additional written notifications disclosing all changes in membership.

On June 16, 2016, AIM Photonics filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on July 25, 2016 (81 FR 48450).

The last notification was filed with the Department on August 19, 2021. A notice was published in the **Federal**

Register pursuant to Section 6(b) of the Act on October 5, 2021 (86 FR 55001).

Suzanne Morris,

Chief, Premerger and Division Statistics, Antitrust Division.

[FR Doc. 2022-00581 Filed 1-12-22; 8:45 am]

BILLING CODE 4410-11-P

DEPARTMENT OF JUSTICE

Antitrust Division

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium

Notice is hereby given that, on November 29, 2021, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical Technology Enterprise Consortium (“MTEC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances.

Specifically, Integration Innovation Inc., Huntsville, AL; HackerOne, San Francisco, CA; Advanced Materials and Devices, Inc., Reno, NV; Cimarron Software Services Inc., Houston, TX; Delta Chase LLC., West Chester, OH; Virginia Commonwealth University, Richmond, VA; H&H Medical Corporation, Williamsburg, VA; Spectrohm Inc. Tysons Corner, VA; Rubix LS, Lawrence, MA; University of Florida, Gainesville, FL; Phagelux (Canada) Inc., Montréal, CAN; Next Science, LLC., Jacksonville, FL; BlackBox Biometrics, Inc. (B3) Rochester, NY; VitaCyte LLC., Indianapolis, IN; Synedgen, Inc., Claremont, CA; KeriCure Medical, Wesley Chapel, FL; Kurve Technology Inc., Lynnwood, WA; SweetBio, Inc. Memphis, TN; DLH Silver Spring, MD; Novel Technologies Holdings Limited, Manchester, NH; KERECIS Limited, Isafjordur, ISL; NanoOxygenic LLC., Dallas, PA; Georgia State University Research Foundation, Inc. Atlanta, GA; Retia Medical LLC., Valhalla, NY; AivoCode Inc. La Jolla, CA; Medical Informatics Corp., Houston, TX; Technatomy Corporation Fairfax, VA; Terida LLC. Pinehurst, NC; Appili Therapeutics, Inc., Halifax, CAN; Continuous Precision Medicine(CPM) Research, Triangle Park, NC; Overseas Strategic Consulting, Ltd, Philadelphia, PA; Vizbii Technologies, Inc.,

Charleston, SC; Anthem Engineering LLC., Elkridge, MD; Perfusion Medical, LLC. Reston, VA; New York University, New York, NY; Catharsis Productions, Chicago, IL; University of New Hampshire Durham, NH; Aldyn, Boston, MA; GEN-AVIV LLC., North Miami Beach, FL; NeuroFlow, Inc., Philadelphia, PA; Advancement Strategy, LLC., Columbia, MD.; Belle Artificial Intelligence Corporation, Cambridge, MA; Diagnoss Inc, Pomona, CA; San Diego State University, San Diego, CA; Dovel Technologies, McLean, VA; ASSURSEC, LLC., LEESBURG, VA; Rhode Island Hospital, Providence, RI; University of Connecticut, Storrs, CT; Alertgy, Inc. MELBOURNE, FL; Boston University, Boston, MA; MBio Diagnostics, Inc. dba LightDeck Diagnostics, Boulder, CO; Pacific Institute for Research and Evaluation, Beltsville, MD; Tactical Medical Solutions, LLC., Anderson, SC; ViiNetwork, Inc., ViiMed, Washington, DC; Renaissance Biotech, LLC., Malibu, CA; Bio1 Systems, Inc., San Carlos, CA; DataRobot, Boston, MA; Knowesis Inc., Fairfax, VA; MassBiologics of the UMMS, Boston, MA; SOLUTE Inc., San Diego, CA; Aktiv Pharma Group, Broomfield, CO; Bettermeant, Inc., Berkeley, CA; SanMelix Laboratories, Inc., Hollywood, FL; Viscus Biologics LLC., Cleveland, OH; Guidehouse Inc. Falls Church, VA; Movement Rx Physical Therapy, P.C., San Diego, CA; Promethean LifeSciences, Inc., Pittsburgh, PA; Tygrus LLC., Troy, MI; MiMedx Group, Inc., Marietta, GA; Neomatrix Therapeutics, Inc., Stony Brook, NY; PuraLab LLC., Wilsonville, OR; InterSystems Corporation, Cambridge, MA; Full Spectrum Omega, Inc., Los Angeles, CA; Rockland Technimed Limited, Mahwah, NJ; MediWound, Ltd., Yavne, ISR; Primmune Therapeutics, Inc., San Diego, CA; Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI; Emmes Company LLC., Rockville MD; Canvas Incorporated, Huntsville, AL; Purgo Scientific, LLC., South Jordan, UT; Dascena, Houston, TX; Through The Cords LLC., Salt Lake City, UT; Armed Forces Services Corporation dba Magellan Federal, Arlington, VA; Immuron Limited, Victoria, AUS; Terumo BCT Biotechnologies, LLC., Lakewood, CO; TourniTek, Seattle, WA; West Therapeutic Development, LLC., Northbrook, IL; Maryland Development Center, Baltimore, MD; Tessonics Medical Systems Inc., BIRMINGHAM, MI; Vir Biotechnology, San Francisco, CA; Wound Exam Corp., Beverly Hills, CA; Creare LLC., Hanover, NH; Drexel